NOXXON ANNOUNCES DATA SECURITY SUPERVISORY BOARD
VALIDATES THE HIGHEST DOSE OF NOX-A12 IN THE PHASE 1/2 BRAIN CANCER TRIAL
Berlin, Germany, May 10, 2021, 6:00 p.m. CEST – NOXXON Pharma NV (Euronext Growth Paris: ALNOX), a biotechnology company focused on improving cancer treatments by targeting the tumor microenvironment (TME), today announced that an independent Data Safety Oversight Board (DSMB) has confirmed that the highest dose high of NOX-A12in combination with radiotherapy in the ongoing phase 1/2 study in patients with brain cancer is safe and that the trial should continue as planned.
The study examines three dosing regimens of NOX-A12 (200, 400 and 600 mg / week), each combined with external beam radiation therapy in patients with newly diagnosed brain cancer. DSMB’s recommendation to proceed followed the safety data analysis stipulated in the study protocol after the three patients in the third – and final – cohort have completed at least four weeks of treatment at the highest dose. .
“We are pleased that the DSMB analysis concluded that the highest dose of NOX-A12 in this Phase 1/2 study in brain cancer patients is safe. data for cohort 2 at the end of May and cohort 3 in November 2021, ” commented Aram Mangasarian, CEO of NOXXON.
For more information please contact:
NOXXON Pharma NV Aram Mangasarian, Ph.D. Managing Director Tel. +49 (0) 30 726247 0 [email protected]
LifeSci Advisors Guillaume van Renterghem Tel. +41 (0) 76 735 01 31 [email protected]
NewCap Arthur Rusty
Phone. +33 (0) 1 44 71 00 15 [email protected]
NOXXON’s oncology-focused pipeline acts on the tumor microenvironment (TME) and the cancer immunity cycle by breaking down the tumor protective barrier and blocking tumor repair. By neutralizing the chemokines in TME, NOXXON’s approach works in combination with other forms of treatment to weaken tumor defenses against the immune system and allow greater therapeutic impact. NOXXON’s main program, NOX-A12, provided the final peak data of a Keytruda® combination trial in patients with metastatic colorectal and pancreatic cancer published at the ESMO conference in September 2020 and based on the results of the trial, including overall survival and safety profile, more studies are planned in pancreatic cancer. NOXXON is also studying NOX-A12 in brain cancer in combination with radiation therapy which has been granted orphan drug status in the US and EU for the treatment of certain brain cancers. A trial of NOX-A12 in combination with radiation therapy in newly diagnosed brain cancer
patients who will not benefit from standard chemotherapy provided preliminary data from the first cohort showing consistent tumor reductions. The company’s second clinical active ingredient, NOX-E36, is a phase 2 TME active targeting the innate immune system. NOXXON plans to test NOX-E36 in patients with solid tumors as monotherapy and in combination. You can find more information on: www.noxxon.com
Keytruda® is a registered trademark of Merck Sharp & Dohme Corp
Certain statements in this communication contain wording or terms that refer to future or future developments, as well as negations of such wordings or terms, or similar terminology. These are described as forward-looking statements. In addition, all information contained in this communication concerning the expected or future results of the business segments, financial indicators, changes in the financial situation or other financial or statistical data contains such forward-looking statements. The company cautions potential investors not to rely on these forward-looking statements as certain predictions of actual future events and developments. The company is neither responsible nor responsible for updating this information, which only represents the inventory on the day of publication.
Noxxon Pharma NV published this content on May 10, 2021 and is solely responsible for the information contained therein. Distributed by Public, unedited and unchanged, on 10 May 2021 03:51:02 PM UTC.